Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Novartis’ Entresto, Mayzent Up for MHLW Panel Review in Round Robin Method
April 20, 2020
- Japan Declares Nationwide State of Emergency
April 17, 2020
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- Novartis’ Flawed and Delayed Inquiry Responses in Zolgensma Review “Extremely Unusual”: PMDA Report
April 16, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- MHLW Asks Drug Makers, Wholesalers to Reduce People Coming to Work by “at Least 70%”
April 15, 2020
- Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
- MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
- 15 Insulins, Erleada, Faslodex under PMDA Safety Review
April 13, 2020
- MHLW Urges Drug Makers, Wholesalers to Ensure Stable Drug Supplies amid Emergency
April 10, 2020
- MHLW Plans to Revise National Vaccine Certification Rules in June
April 10, 2020
- League of Lawmakers Urges MHLW to Help COVID-19 Drug/Vaccine Development
April 10, 2020
- Chuikyo Allows Round Robin Meetings for Coronavirus-Related Matters
April 9, 2020
- Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
- PMDA to Accept Trial Notifications by Email amid Coronavirus Outbreak
April 9, 2020
- MHLW Staffer Infected with Novel Coronavirus
April 9, 2020
- Talks with Regulators Ongoing for Ferinject, Zeria Says after Skipping Listing 4 Times
April 9, 2020
- AMED Invites Research Projects for COVID-19 Vaccine Development from Mid-April
April 9, 2020
- World’s 1st Topical JAK Inhibitor Corectim, AbbVie’s Rinvoq, Bayer’s Nubeqa OK’ed for Listing on April 22
April 8, 2020
- Novartis Japan Chided over Flawed Zolgensma Data, Delayed Responses
April 8, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…